Neogen’s fiscal Q4 2026 earnings call drew the CEO, CFO, Chief Commercial Officer, and Chief Scientific Officer to discuss results and guidance.
Q4 revenue reached $225.3 million, up 4.3% on a core basis; food safety revenue was $166.8 million with 5.8% core growth.
Animal safety returned to positive core growth at 0.5% as supply constraints eased; total revenue rose 7% sequentially.
Fiscal 2027 guidance: revenue $880-$885 million, adjusted EBITDA $180-$182 million; assumes $92 million revenue and $13 million EBITDA from genomics.
PetriFilm transition targets sellable output with a multi-quarter shift starting November 2026; first SKU validation expected in August; 200-300 bps gross margin upside is seen in FY28.
NEOG•
